Leland van den Daele

Light at the End of the Covid-19 Tunnel

The US Covid-19 pandemic may soon abate. A typical pattern of deaths from Covid-19 within a confined geographic/demographic boundary is characterized by rapid increase of deaths during a 4 to 6-week period followed by gradual decline during a 12 to 14-week period to near baseline. Deaths follow infections from 2.5 to 4-weeks, so rising infections precede rising deaths. The pattern of rapid rise with a sloping tail characterized New York State, New Jersey, Sweden, Lombardy region of Italy, London, and geographic areas where the virus failed to be initially contained (Figure 1).

Figure 1: Illustration of rise and rapid fall of daily deaths. Chart is logarithmic, so the increase in deaths is normalized. Graphs are similar for metropolitan regions in the US North East during the initial phase of Covid-19 infections. The same pattern is likely to repeat in yet unaffected populous areas of the US. This continuing spread to “virgin” areas is why the US displays a irregular decline, and in fact, when the graph is updated may show a rise at the tail end before precipitous drop-off.

Who dies?

During the period of uncontrolled spread, the virus gained a wide foothold. A portion of the population appeared immune, another portion had only a mild bout. Most of the population were asymptomatic, particularly youth and young adults. What occurred was that the vulnerable died. A superb graphic from a Danish study titled “Characteristics and predictors of hospitalization and death in the first 9,519 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: A nationwide cohort” provides a heatmap for risk of death from Covid-19 in the Danish population (Figure 2). The Infection Fatality Rate (IFR) varies by age group and condition. The same clarity of data is not available from the Center for Disease Control and Prevention (CDC) since deaths and comorbidities are reported independently and vary state by state. However, the Danish data provides a reasonable proxy for the US.

Figure 2. Heatmap illustrating mortality among SARS-CoV-2 PCR positive cases, specified by age and number of comorbidities. “Total number of comorbidities is assessed as the total number of any of the following conditions: Chronic lung disease, hypertension, ischemic heart disease, heart failure, atrial fibrillation, stroke, diabetes, dementia, cancer, chronic liver disease, hospital-diagnosed kidney disease, alcohol abuse, substance abuse, major psychiatric disorder, organ transplantation, overweight and obesity, and rheumatoid arthritis/connective tissue disease (Reilev et al, 2020, p 23).”

The Danish IFR for the 50 to 59 year old cohort with two health challenges is approximately 1.0; for the 60 to 69 year old cohort, approximately 5.0; for the 70 to 79 year old, 14.0; for the 80 to 89 year old, 26.0; and for the 90 to 99 year old, 49.0. The IFR for persons under 50 may be close to the value postulated by John Ioannidis, the Stanford epidemiologist, of 0.28. However, America ranks 46th in longevity among the world’s nations with high incidences of obesity, hypertension, and diabetes. The US is not Denmark. About 40% of US adults are clinically obese, 30% have hypertension, 10% are diabetic, and so the aggregate number of US citizens with “comorbidities” ranges from 20 to more than 50% depending upon age group. Therefore, the IFR for US persons under age 50 likely exceeds that of Denmark.

Need for Reappraisal of Covid-19 Trajectory

The view that herd immunity will be so readily obtained is not in accord with current guidance. The common view persists that herd immunity requires at least 60-80% of a population to be immune to the pathogen. This may be true in a “bounded, freely interacting group” where everybody has access to everybody else, and where every member has the same chance to be infected. But this is not the real world. Two factors mitigate against the “classical herd immunity” view that 60 to 80% of the population must be immune for the virus to stop circulating. The first factor is mathematical modeling of community spread, and the second is individual differences in immune resistance to the pathogen.

Herd Immunity Reconsidered

In the world persons occupy, groups are segmented by geography, occupation, living arrangements, family membership, travel habits, and a host of other variables. Persons that are most likely to be in close contact with a variety of people are most likely candidates to be infected and be carriers of the virus. These are people who take public transportation, meet face-to-face with the public, checkout stations; retail, factory, and office workers in tight quarters; service personnel, participants at conventions, fairs, and workshops, waiters at restaurants, transit police, attendees on cruise ships, hospital personnel, and the like.

In fact, all things being equal, risk can be calculated as a function of number of contacts, time in contact, and spatial distance among them. In the real world, people, high in risk are the people who catch and spread the virus. At the other extreme, homebodies just stay home. The high-risk group spreads the virus among themselves, sometimes “spilling over” into a low-risk demographic, but the low-risk demographic is self-limiting. The high-risk group rapidly infect one another, and like kindling burns brightly then quickly burns out.

A mathematical model of herd immunity divided groups into low interactive, average interactive, and high interactive. When interaction occurred predominantly within groups, the virus–induced herd immunity equaled 43% rather 60%. Proportionally, more persons were infected in groups with high contact than in groups with low contact. Acquired immunity for those most likely to carry the infection was therefore higher, and the overall rate of infection for the general population lower than if immunity was uniformly distributed as in classical herd immunity.

Viral Resistance

Immune responses to the virus include mobilization of T cells, intracellular responses, and production of antibodies. Memory T cells are likely instrumental in warding off infection. Research led by the La Jolla Institute for Immunology detected SARS-CoV-2-reactive CD4+ T cells in approximately 40%–60% of unexposed individuals, “suggesting cross-reactive T cell recognition between circulating “common cold” coronaviruses and SARS-CoV-2.” T cell intervention can confer partial or complete immunity to the Corona virus.

In addition, adaptive intracellular responses restore cellular integrity. A study in the Journal Trends in Pharmacological Sciences, conjectures, “ activation of transcription factor nuclear factor erythroid 2 p45-related factor 2 (NRF2) promotes resolution of inflammation and, in parallel, restores cellular redox and protein homeostasis, and facilitates tissue repair.” Thus, epigenetic variation may trigger intracellular processes to reinstate functionality following Covid-19 infection.

Finally, a great deal of public attention has been directed to antibodies since these are produced as a reaction to the disease and a marker for vaccine development. Types of antibodies and their kinetics appear to differ in symptomatic and asymptomatic persons. Covid-19 antibodies increase with the severity of the illness and wane in the months following illness.

T cell immunity likely provides a first line of defense to Covid-19. An adequate T cell response to the pathogen makes less likely a vigorous antibody response since the pathogen has been neutralized. Persons with compromised T cell production are usually sickest. The 40-60% of persons with T-cell cross-reactivity to Covid-19 likely proportionately increase herd-immunity.

The US Mega-Nation

After spiking in April due to the runaway infections in the New York metropolitan area, US infections trended downward until mid-July. Since the low, deaths approximately doubled into early August. However, deaths remained low in the New York metropolitan area and the North East US. The upward trend is almost entirely due to increased deaths in the South, South Western, and Western US. The demographic groups affected in these states are largely young adults visibly present at beach gatherings, partying, and protests (Figure 3).

Figure 3: US Covid-19 Deaths. During March and April, deaths rose rapidly in the North East and the NY Metropolitan region, then fell to near baseline. Since early to mid-July, deaths are rising in the South and West, and have yet to decline. The chart sums across these regions. The seesaw variation occurs because deaths are not reported on weekends.

Other developing hotspots include cities in the Midwest and California’s Central Valley. These areas are generally less traveled, working class and farm areas late in exposure to the virus and prone to seasonal changes in work patterns and social aggregation. Poverty and comorbidities are higher among these demographics and so the Infection Fatality Rate (IFR) will be higher.

Earlier cohorts of Covid-19 patients in hospital intensive care units were comprised largely of older adults. Younger patients from the Sunbelt states are less likely to have comorbidities, less likely to die, and more likely to recover with fewer long-term sequelae. As many as 80% are asymptomatic, and most who are ill stay at home. This does not mean that symptomatic young adults escape convalescence or complications as “Covid-19 long-haulers” attest.

But just as in countries and states where Covid-19 was rampant, the pattern of Covid-19 infections follows the same rules: infections quickly spike within 4 to 6 week period followed by a taper to baseline within a 12 to 14 week period. Once this pattern has repeated itself in US locations where infections were low or non-existent, herd immunity will have been established. An infected carrier introduced into a community will not find suitable hosts –except for social isolates and insulated groups.

Conclusion

The US is highly diverse by age, culture, and geography. When partitioned, each group has its own activity level and transmission rate. The upper limit for herd immunity for the US overall is likely to be less than classical herd immunity. This is so because age, culture, and geography provide additional boundaries to interaction with highly proximate groups likely to first acquire and obtain immunity to the virus. These are the past and current hotspots. Hotspots flare-up then retreat.

The protesting, mixing, and partying that has characterized large swaths of the US may reflect a primal adaptation to speed herd immunity. Precisely those groups most likely to spread the virus to less active groups are cleansing their group by sharing the virus among themselves, thereby reducing the likelihood of transmission to the general population. Sequestered groups remain relatively unaffected. Based on mathematical modeling, herd immunity is likely to fall between 40 to 60%. If as research suggests, 40 to 60% of the population possess cross-reactive T cells, immunity is again enhanced by a large fraction. The lower value for herd immunity and the unexpected high incidence for cross-reactive T cell immunity among individuals is consistent with data from serological antibody tests to Covid-19 in the range of 12 to 18 percent found in community studies following return to baseline after rampant Covid-19 infection.

The current round of US Covid-19 infection remains dangerous to susceptible groups. Social distancing, masks, hand-washing, and other precautions ought to be practiced. However, the updated model of herd immunity, and new findings from cross-T cell immunity, mechanisms of cellular resistance, and Covid-19 serology suggest that the Covid-19 fire may soon turn to embers. After the hotspots have been consumed, infectious risk is likely to fall dramatically. Much of ordinary life will resume.

If the timeline for current infections in the US follows the same timeline as the virus followed in other locals, the worst of the Southern and Western flare-ups will have abated by early November. As the virus works its way to communities that have remained unaffected to the present, the virus will have followed its course by the end of March. After that, an occasional flare-up may occur, but without the dire risk attendant to virgin territory. Of course, all this is baring a new variety of the virus that evades earlier immunity, then a new chapter must be written.


Posted

in

by

Comments

127 responses to “Light at the End of the Covid-19 Tunnel”

  1. canadian cialis no prescription

    canadian cialis no prescription

  2. imiquimod pharmacy

    imiquimod pharmacy

  3. rohypnol mexico pharmacy

    rohypnol mexico pharmacy

  4. when to take tadalafil

    when to take tadalafil

  5. female viagra no prescription

    female viagra no prescription

  6. vardenafil vs tadalafil

    vardenafil vs tadalafil

  7. order viagra no prescription

    order viagra no prescription

  8. pharmacy warfarin protocol

    pharmacy warfarin protocol

  9. cialis side effects a wife’s perspective

    cialis side effects a wife’s perspective

  10. sildenafil discount

    sildenafil discount

  11. buy generic viagra soft tabs

    buy generic viagra soft tabs

  12. female pink viagra

    female pink viagra

  13. real viagra without a prescription

    real viagra without a prescription

  14. purchase viagra safely online

    purchase viagra safely online

  15. generic viagra online pharmacy canada

    generic viagra online pharmacy canada

  16. generic for cialis in the usa

    generic for cialis in the usa

  17. buying cialis generic

    buying cialis generic

  18. cialis black buy in australia

    cialis black buy in australia

  19. cialis american express

    cialis american express

  20. transdermal metronidazole

    transdermal metronidazole

  21. gabapentin 00mg

    gabapentin 00mg

  22. sulfamethoxazole-trimethoprim clinical use

    sulfamethoxazole-trimethoprim clinical use

  23. valacyclovir pka

    valacyclovir pka

  24. can pregabalin cause seizures

    can pregabalin cause seizures

  25. tamoxifen teeth

    tamoxifen teeth

  26. lisinopril hartkloppingen

    lisinopril hartkloppingen

  27. glucophage manufacturer

    glucophage manufacturer

  28. molecola furosemide

    molecola furosemide

  29. animal in rybelsus commercial

    animal in rybelsus commercial

  30. rybelsus kidney stones

    rybelsus kidney stones

  31. semaglutide 96 units

    semaglutide 96 units

  32. flagyl utslag

    flagyl utslag

  33. zoloft cost without insurance

    zoloft cost without insurance

  34. cymbalta snri

    cymbalta snri

  35. is 1000 mg of cephalexin too much

    is 1000 mg of cephalexin too much

  36. best time to take duloxetine 30 mg

    best time to take duloxetine 30 mg

  37. what is escitalopram

    what is escitalopram

  38. cheap viagra 100 online

    cheap viagra 100 online

  39. is keflex safe for pregnancy

    is keflex safe for pregnancy

  40. fluoxetine for kids

    fluoxetine for kids

  41. gabapentin somministrazione

    gabapentin somministrazione

  42. natural amoxicillin

    natural amoxicillin

  43. ciprofloxacin brand name

    ciprofloxacin brand name

  44. can you drink with cephalexin

    can you drink with cephalexin

  45. bactrim vs amoxicillin

    bactrim vs amoxicillin

  46. can you eat ice cream while taking bactrim

    can you eat ice cream while taking bactrim

  47. effexor 150 mg

    effexor 150 mg

  48. how long does augmentin take to work

    how long does augmentin take to work

  49. flomax off label use in women

    flomax off label use in women

  50. ezetimibe chemical name

    ezetimibe chemical name

  51. diclofenac sodium topical gel 1%

    diclofenac sodium topical gel 1%

  52. ddavp chemotherapy

    ddavp chemotherapy

  53. successfully coming off citalopram 10mg

    successfully coming off citalopram 10mg

  54. cozaar vs benicar

    cozaar vs benicar

  55. diltiazem calcium channel blocker

    diltiazem calcium channel blocker

  56. contraves 7-segment anzeige

    contraves 7-segment anzeige

  57. how does flexeril work

    how does flexeril work

  58. depakote vs lamictal

    depakote vs lamictal

  59. aripiprazole uses

    aripiprazole uses

  60. amitriptyline for sleep and anxiety

    amitriptyline for sleep and anxiety

  61. is aspirin ibuprofen

    is aspirin ibuprofen

  62. how long does it take for allopurinol to lower uric acid levels?

    how long does it take for allopurinol to lower uric acid levels?

  63. celecoxib vs ibuprofen

    celecoxib vs ibuprofen

  64. celexa and adderall

    celexa and adderall

  65. is buspar addictive

    is buspar addictive

  66. baclofen dose

    baclofen dose

  67. how does bupropion make you feel

    how does bupropion make you feel

  68. augmentin strengths

    augmentin strengths

  69. buy ashwagandha

    buy ashwagandha

  70. abilify 5 mg

    abilify 5 mg

  71. remeron vs wellbutrin

    remeron vs wellbutrin

  72. glyburide vs repaglinide

    glyburide vs repaglinide

  73. protonix dose

    protonix dose

  74. joint pain semaglutide

    joint pain semaglutide

  75. what is robaxin 750

    what is robaxin 750

  76. actos pdr

    actos pdr

  77. obat acarbose.pdf

    obat acarbose.pdf

  78. ivermectin syrup

    ivermectin syrup

  79. spironolactone therapeutic use

    spironolactone therapeutic use

  80. synthroid crying

    synthroid crying

  81. can i take amitriptlyene with voltaren

    can i take amitriptlyene with voltaren

  82. venlafaxine withdrawl

    venlafaxine withdrawl

  83. is sitagliptin and vildagliptin same

    is sitagliptin and vildagliptin same

  84. tizanidine hcl 4mg side effects

    tizanidine hcl 4mg side effects

  85. tamsulosin iris

    tamsulosin iris

  86. cialis online pills

    cialis online pills

  87. free tadalafil

    free tadalafil

  88. sildenafil brand

    sildenafil brand

  89. compounding pharmacy low dose naltrexone

    compounding pharmacy low dose naltrexone

  90. levitra 40 mg reviews

    levitra 40 mg reviews

  91. cialis bangkok pharmacy

    cialis bangkok pharmacy

  92. how long does 20mg sildenafil last

    how long does 20mg sildenafil last

  93. 10mg levitra buy

    10mg levitra buy

  94. sildenafil tadalafil vardenafil

    sildenafil tadalafil vardenafil

  95. ivermectin generic name

    ivermectin generic name

  96. buy stromectol pills

    buy stromectol pills

  97. vardenafil dosage 40 mg

    vardenafil dosage 40 mg

  98. viagra professional pfizer

    viagra professional pfizer

  99. stromectol 3 mg tablets price

    stromectol 3 mg tablets price

  100. stromectol tab

    stromectol tab

  101. tadalafil/oxytocin sublingual troches

    tadalafil/oxytocin sublingual troches

  102. stromectol 0.5 mg

    stromectol 0.5 mg

  103. ivermectin 3mg dosage

    ivermectin 3mg dosage

  104. buy liquid tadalafil

    buy liquid tadalafil

  105. viagra 100mg cost in india

    viagra 100mg cost in india

  106. trazodone dosage for anxiety

    trazodone dosage for anxiety

  107. nolvadex vs arimidex

    nolvadex vs arimidex

  108. valtrex dosage cold sores

    valtrex dosage cold sores

  109. can you drink while on amoxicillin

    can you drink while on amoxicillin

  110. keflex for cellulitis dose

    keflex for cellulitis dose

  111. lyrica for nerve pain

    lyrica for nerve pain

  112. how to stop diarrhea from metformin

    how to stop diarrhea from metformin

  113. can i drink alcohol while taking cephalexin

    can i drink alcohol while taking cephalexin

  114. is 2.5 mg lisinopril a low dose

    is 2.5 mg lisinopril a low dose

  115. medications ciprofloxacin

    medications ciprofloxacin

  116. provigil everyday

    provigil everyday

  117. side effects doxycycline

    side effects doxycycline

  118. levitra cialis order

    levitra cialis order

  119. “vardenafil hcl tabs \”no prescription\” india pharmacy”

    “vardenafil hcl tabs \”no prescription\” india pharmacy”

  120. how long does it take for watermelon viagra to work

    how long does it take for watermelon viagra to work

  121. tadalafil buy online

    tadalafil buy online

  122. online pharmacy without prescriptions

    online pharmacy without prescriptions

  123. sildenafil interactions with alcohol

    sildenafil interactions with alcohol

  124. sildenafil roman

    sildenafil roman

  125. is sildenafil covered by insurance

    is sildenafil covered by insurance

  126. sildenafil mechanism of action

    sildenafil mechanism of action

  127. sildenafil 50 mg price

    sildenafil 50 mg price